This interim analysis shows data from five large private center about all patients with SOF-based Treatment this Janu-ary-to May 2014. Results:190 patients ( 110 male, 80 female) received SOF-based treatment. 115 patients with genotype 1 (54 1a, 61 1b) 12 genotype 2, 45 genotype 3, 18 genotype 4. Treatment-naive were 65, relapse 67, nonresponse 58. 89 patients had

fibrosis 3-4. 12 patients received SOF/ Riba for 12 weeks (all G2), 123 received the triple therapy 12 weeks, 31 SOF+Daclatasvir (all F4), 5 SOF + Simeprevir, 19 SOF+Riba aimed for 24 weeks (pat. started before approval of Simeprevir and all with IFN contraindications). 4 patients with IFN based therapy had to stop treatment because of side effects. 175 of 184 GPCR Compound Library were HCV-RNA neg. at week 4, 7 were < 25IU/ml but detectable. Anemia

and fatigue were the most reported AEs. No severe side effects occurred. Results of EOT and SVR12 are pending. Conclusion: These results suggest that SOF-based therapy under real life conditions is mainly used as triple therapy for 12 weeks and given to experienced patients and patients with advanced fibrosis as recommended. Adverse events and treatment discontinuations were low. LEE011 Disclosures: Peter Buggisch – Advisory Committees or Review Panels: Janssen, AbbVie, BMS, Siemens; Speaking and Teaching: Roche, MSD, Gilead Holger Hinrichsen – Advisory Committees or Review Panels: Janssen, Gilead, Abbvie; Speaking and Teaching: Roche, MSD Stefan Mauss – Advisory Committees or Review Panels: BMS, AbbVie, Janssen, Roche, Gilead; Speaking and Teaching: BMS, AbbVie, Janssen, Gilead Dietrich Hueppe – Advisory Committees or Review Panels: MSD, Gilead, Abbvie, BMS, Novartis, Norgine Joerg Petersen – Advisory Committees or Review Panels: Bristol-Myers Squibb, Gilead, 上海皓元 Novartis, Merck, Bristol-Myers Squibb, Gilead, Novartis, Merck; Grant/ Research Support: Roche, GlaxoSmithKline, Roche, GlaxoSmithKline; Speaking and Teaching: Abbott, Tibotec, Merck, Abbott, Tibotec, Merck The following people have nothing to disclose: Karl-Georg Simon Background: The

achievement of early virologic response (EVR) during triple therapy of chronic HCV genotype 1 infection with the HCV protease inhibitor boceprevir has been identified as predictor to shorten treatment to 24 weeks. The present interim analysis of the NOVUS observational study was aimed to determine the frequency of EVR during boceprevir triple therapy in German real-life and to determine the virologic outcome of patients with and without EVR. Methods: From April 2012 until January 2014, 536 patients (pts) with genotype 1 infection were recruited in the ongoing NOVUS study by 97 practices and hospitals in Germany. Patients were treated with pegylated interferons (PegIFN) and ribavirin (RBV) together with BOC for 24 to 44 weeks after a 4 weeks lead-in period with PegIFN/RBV. The present interim analysis was restricted to 222 previously untreated patients with documented HCV-RNA at treatment week (TW) 8.